Abstract: TH-PO0333
Cardiovascular and Thromboembolic Event Risks in Nephrotic Syndrome
Session Information
- Hypertension and CVD: Clinical - 1
November 06, 2025 | Location: Exhibit Hall, Convention Center
Abstract Time: 10:00 AM - 12:00 PM
Category: Hypertension and CVD
- 1602 Hypertension and CVD: Clinical
Authors
- Mashayekhi, Mahtab, Loma Linda University Medical Center, Loma Linda, California, United States
- Gholizadeh Ghozloujeh, Zohreh, Loma Linda University Medical Center, Loma Linda, California, United States
- Heidari-Bateni, Giv, Arrowhead Regional Medical Center, Colton, California, United States
- Abdi Pour, Amir, Loma Linda University Medical Center, Loma Linda, California, United States
- Mathew, Roy O., Loma Linda University Medical Center, Loma Linda, California, United States
- Norouzi, Sayna, Loma Linda University Medical Center, Loma Linda, California, United States
Background
Nephrotic syndrome (NS) is associated with increased risk of cardiovascular events (CVE) due to hyperlipidemia, prothrombotic state, persistent inflammation, and endothelial dysfunction. In this study we examined the effect of different epidemiologic factors on CVE and venous thromboembolism (VTE) in patients with NS.
Methods
This is a retrospective cohort study included 100 patients diagnosed with NS. Bivariate analyses were performed using chi-square tests to compare demographic and clinical characteristics between patients with and without CVE (Myocardial infarction, Stroke, Unstable angina, or Heart failure) and VTE events. Multivariate logistic regression models were constructed to identify independent predictors of both CVE and VTE while controlling for potential confounding variables.
Results
The study examined 100 patients with nephrotic syndrome (NS) with an equal gender distribution (50% female, 50% male). Cardiovascular events (CVE) were common, with 16% having a history of CVE prior to NS diagnosis and 55% experiencing a CVE after NS diagnosis. 11% had a history of VTE, while 20% developed VTE after NS diagnosis. In univariate analyses, prior CVE history was significantly associated with subsequent CVE events (p<0.001), while gender and income level showed no significant associations with either CVE or VTE outcomes. In multivariate analysis, prior CVE history showed a substantial but non-significant association with subsequent CVE events (aOR=8.077, 95% CI: 0.506-128.911, p=0.139). Patients receiving steroid treatment had approximately 96% lower odds of developing CVE compared to those not on steroids (aOR=0.036, 95% CI: 0.005-0.243, p<0.001).
Conclusion
CV and VTE events were common in nephrotic syndrome patients. Steroid use was associated with a reduced risk of cardiovascular events. No strong predictors were identified for VTE in our study.